Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

Anoro
Read More
GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).
July 31, 2018
Find out more
Reyataz
Read More
The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost.
June 28, 2019
Find out more
Ygalo
Read More
Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine
August 9, 2018
Find out more
Lu AF35700
Read More
Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors.
March 19, 2018
Find out more
Invega Sustenna/Invega Trinza
Read More
Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are long-acting injectable formulations developed by Johnson & Johnson, using with Alkermes’s technology.
March 19, 2018
Find out more
solithromycin
Read More
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.
June 19, 2015
Find out more
CB-839
Read More
Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.
March 6, 2019
Find out more
omadacycline
Read More
Omadacycline (Paratek Pharmaceuticals) is the first agent of the aminomethycyclines class of antibiotics. The drug, which is a semisynthetic derivative of the tetracycline minocycline.
June 19, 2015
Find out more
Plavix
Read More
Plavix is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.
July 2, 2018
Find out more
Otezla
Read More
Otezla (apremilast; Celgene) is a novel small molecule phosphodiesterase 4 (PDE4) inhibitor that has been shown to modulate the production of pro-inflammatory mediators including tumor necrosis factor alpha, interleukin (IL)-2, IL-17, IL-23, interferon-gamma, leukotrienes, and nitric oxide synthase.
May 18, 2018
Find out more
Macugen
Read More
Macugen (pegaptanib; Valeant/Pfizer) is a PEGylated oligonucleotide aptamer which binds selectively

to vascular endothelial growth factor (VEGF)-165, an isoform of VEGF found to induce angiogenesis

and increase vascular permeability (Natarajan, 2013).
April 7, 2016
Find out more
C-Cure
Read More
C-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions.
December 11, 2017
Find out more
Spiriva
Read More
Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD) and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device.
July 31, 2018
Find out more
Azilect
Read More
Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.
June 21, 2018
Find out more
Quinsair
Read More
Quinsair is an inhaled formulation of the antibiotic levofloxacin that is approved in the EU for the management of chronic pulmonary infections
September 3, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *